HC Wainwright Forecasts Strong Price Appreciation for Balchem (NASDAQ:BCPC) Stock

Balchem (NASDAQ:BCPC) had its price objective upped by HC Wainwright from $185.00 to $190.00 in a research report released on Monday,Benzinga reports. They currently have a buy rating on the basic materials company’s stock. HC Wainwright also issued estimates for Balchem’s Q4 2024 earnings at $1.10 EPS, FY2024 earnings at $4.01 EPS, Q1 2025 earnings at $1.06 EPS, Q2 2025 earnings at $1.09 EPS, Q3 2025 earnings at $1.14 EPS, Q4 2025 earnings at $1.19 EPS and FY2025 earnings at $4.47 EPS.

Separately, StockNews.com raised shares of Balchem from a “hold” rating to a “buy” rating in a research report on Monday, October 28th.

Balchem Stock Performance

BCPC opened at $176.63 on Monday. Balchem has a 12-month low of $116.84 and a 12-month high of $186.03. The firm has a market capitalization of $5.74 billion, a P/E ratio of 47.48, a price-to-earnings-growth ratio of 5.28 and a beta of 0.65. The stock’s 50 day moving average price is $172.07 and its two-hundred day moving average price is $163.86. The company has a quick ratio of 1.90, a current ratio of 2.98 and a debt-to-equity ratio of 0.21.

Institutional Investors Weigh In On Balchem

A number of institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. raised its holdings in Balchem by 3.8% in the 1st quarter. Vanguard Group Inc. now owns 3,935,935 shares of the basic materials company’s stock valued at $609,873,000 after acquiring an additional 144,423 shares in the last quarter. Conestoga Capital Advisors LLC raised its stake in shares of Balchem by 1.8% in the third quarter. Conestoga Capital Advisors LLC now owns 1,175,569 shares of the basic materials company’s stock valued at $206,900,000 after purchasing an additional 20,360 shares in the last quarter. Geneva Capital Management LLC lifted its position in Balchem by 1.7% in the third quarter. Geneva Capital Management LLC now owns 779,869 shares of the basic materials company’s stock worth $137,257,000 after purchasing an additional 12,750 shares during the period. Dimensional Fund Advisors LP boosted its stake in Balchem by 0.9% during the second quarter. Dimensional Fund Advisors LP now owns 697,461 shares of the basic materials company’s stock worth $107,372,000 after buying an additional 5,977 shares in the last quarter. Finally, Congress Asset Management Co. increased its holdings in Balchem by 12.4% in the 3rd quarter. Congress Asset Management Co. now owns 301,440 shares of the basic materials company’s stock valued at $53,053,000 after buying an additional 33,373 shares during the period. 87.91% of the stock is owned by institutional investors and hedge funds.

Balchem Company Profile

Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products.